PA
ORGO icon

PharVision Advisers’s Organogenesis Holdings ORGO Stock Holding History

PharVision Advisers’s Portfolio ORGO Stock Details ORGO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-35,622
Closed -$84.4K – 109
2026
Q1 		$84.4K Sell
35,622
-27,567
-44% -$95.5K 0.86% 60
2025
Q4 		$327K Buy
63,189
+26,488
+72% +$128K 0.17% 228
2025
Q3 		$155K Buy
+36,701
New +$171K 0.09% 567

Other funds holding ORGO

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

PharVision Advisers's ORGO Position: Q2 2026 in Review

PharVision Advisers sold out of Organogenesis Holdings (ORGO) in Q2 2026, closing a stake of 35,622 shares — an estimated $84.4K sold.

PharVision Advisers first reported a position in ORGO in Q3 2025 and held it in 3 quarters. The position peaked at $327K in Q4 2025. 136 funds tracked by Wall St. Rank hold ORGO as of Q2 2026.

  • PharVision Advisers reported no remaining Organogenesis Holdings position as of Q2 2026 after selling out during the quarter.
  • PharVision Advisers sold 35,622 Organogenesis Holdings shares in Q2 2026, an estimated $84.4K.
  • PharVision Advisers first reported a position in Organogenesis Holdings in Q3 2025 and held it in 3 quarters.
  • PharVision Advisers's Organogenesis Holdings position peaked at $327K in Q4 2025.
  • 136 funds tracked by Wall St. Rank held Organogenesis Holdings as of Q2 2026.

Based on PharVision Advisers's 13F filing for Q2 2026, filed 11 Aug 2026.